title: Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia.
authors.affiliation: Barnes Retina Institute, and the Department of Ophthalmology and Visual Science, Washington University School of Medicine, St Louis, MO 63144, USA.
authors.forename: Asheesh
authors.initials: A
authors.lastname: Tewari
authors.forename: Mandeep S
authors.initials: MS
authors.lastname: Dhalla
authors.forename: Rajendra S
authors.initials: RS
authors.lastname: Apte
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D047728:Myopia, Degenerative / Q000150:complications*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000276:immunology; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab